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The intestinal immune system ingeniously balances the distinct responses of elimination 
and tolerance of non-self-substances for the creation and maintenance of homeostatic 
environments. Accumulating evidence has recently shown that various lipids, including 
dietary one, are involved in the regulation of intestinal immunity and are associated 
with biophylaxis and immune disorders. Recent advances in the lipidomics allow the 
identification of novel pathways of lipid metabolism and lipid metabolites for the control 
of intestinal immunity. In this paper, we describe the effects and functions of lipids, 
especially sphingolipids and new lipid metabolites originated from dietary oil on the 
immunomodulation and on the development and pathogenesis of allergic diseases in 
the intestine.
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iNTRODUCTiON
A major physiological function of the intestine is the digestion and absorption of food. Simultaneously, 
Vibrio cholera, Escherichia coli, rotavirus, and other pathogenic microorganisms hitch a ride on this 
essential life-sustaining activity to invade the gut. Intestinal tissue is thus simultaneously exposed to 
foreign matter that is harmful (including pathogenic microorganisms) and to the other that is benefi-
cial to the body (including dietary components and commensal bacteria) (1). The intestine functions 
to recognize pathogenic microorganisms that have invaded the body as undesired foreign matter 
and actively eliminate them, while dietary components and gut commensal bacteria are determined 
to be beneficial, and the intestine is regulated to permit their uptake or coexistence in the body. 
The breakdown of this homeostatic maintenance system is a cause of the development of intestinal 
immune disorders, notably infectious diseases, inflammatory bowel disease, and food allergies (2).
Previous studies have identified a range of intracorporeal (e.g., cytokines and chemokines) and 
extracorporeal (e.g., dietary materials and commensal bacteria) factors involved in the regulation of 
intestinal immunity (3–5), and attention has focused on lipids as important molecules in this process 
(6, 7). Technological progresses in the mass spectrometry-based lipidomics enable us to identify new 
pathway and metabolites participating in the immune regulation.
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In this paper, we describe lipid-mediated intestinal immu-
nomodulation, including the role of dietary lipids and new class 
of lipid metabolites, in the physiological and disease conditions.
PRODUCTiON OF CANONiCAL PRO- AND 
ANTi-iNFLAMMATORY LiPiD MeDiATORS 
FROM eSSeNTiAL FATTY ACiDS
Among the long chain-fatty acids, ω3 and ω6 fatty acids are 
essential fatty acids that cannot be produced within the body and 
thus must be ingested from food. The main ω6 fatty acid found 
in dietary oils is linoleic acid (LA) (8). This is metabolized in the 
body to arachidonic acid, which in turn is further metabolized 
to lipid mediators, such as prostaglandin and leukotriene, by 
the action of the enzymes cyclooxygenase (COX), lipoxygenase 
(LOX), and cytochrome P450 (CYP) (8). It is well known that the 
LA-originated metabolites (e.g., prostaglandin E1, E2, and D2, 
lipoxin A4) possess both pro- and anti-inflammatory actions by 
affecting various immune cells (e.g., macrophages, neutrophils, 
and T cells) and non-immune cells (e.g., epithelial cells), which is 
mediated by different types of receptors [e.g., EP1, EP2, EP3, EP4, 
D-type prostanoid (DP), chemoattractant receptor homologous 
molecule expressed on Th2 cells (CRTH2), and ALX] [reviewed 
in Ref. (9, 10)].
The prominent ω3 fatty acid found in dietary oils is 
α-linolenic acid (ALA), which has long been known to have 
anti-inflammatory properties (11, 12). Because LA and ALA 
are both converted to their respective metabolic products by 
the same enzymes (8), the mechanism of action of ALA was 
formerly believed to involve the competitive inhibition of lipid 
metabolism originating with LA. However, recent advances in 
lipidomics technology have shown that in addition to competi-
tive inhibition, ALA also actively participates in bioregulation 
by becoming a precursor of lipid mediators that exhibit an anti-
inflammatory action (6, 11). ALA is metabolized in the body into 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
after which they are metabolized by COX, LOX, and CYP and 
converted into the lipid mediators (e.g., prostaglandin E3, E and 
D series of resolvins, maresins, and protectins) to exert their 
anti-inflammatory actions by inhibiting neutrophil infiltration, 
promoting phagocytosis of neutrophils by macrophages, and 
inhibiting IFN-γ, tumor necrosis factor (TNF)-α, and inducible 
nitric oxide synthase production (6, 11). The mechanisms under-
lying these actions include signal transduction via receptors 
(e.g., GPR40 and GPR120), gene expression (e.g., PPAR family 
and NFκB), and membrane characteristics (e.g., fluidity and lipid 
raft formation) (13, 14).
iNFLUeNCe OF FATTY ACiDS iN DieTARY 
OiLS ON THe DeveLOPMeNT OF GUT 
iMMUNe DiSeASeS
Epidemiological studies indicate the association of inci-
dence of inflammatory disorders and infectious diseases 
with dietary fatty acid composition (15–17) and lipidomics 
analyses identified key lipid metabolites responsible for these 
responses (18, 19).
In addition to inflammatory bowel diseases, food allergies 
are intestinal immune disorders that have become increasingly 
common in recent years. The food allergy occurs as type I 
allergic reactions, with the production of allergen-specific IgE 
as well as activation and degranulation of mast cells (20, 21). 
To examine the effect of dietary oil on the development of food 
allergy, we conducted animal experiments, using special chow 
that contained various dietary oils with a range of different fatty 
acid compositions, and found that differences in the fatty acid 
composition of dietary oils affected the development of food 
allergy (22). Different types of dietary oils vary greatly in their 
fatty acid compositions, and the soybean oil used in regular 
mouse chow contains approximately 50% LA and roughly 5% 
ALA. Linseed oil (also known as flaxseed oil), on the other hand, 
is known to have a high ALA content of approximately 60%, 
more than 10 times higher than that of soybean oil. We therefore 
tested the effect of differences in the proportions of ω6 (LA) and 
ω3 (ALA) fatty acids on the development of food allergy. Mice 
were fed with chow containing either 4% soybean oil (the oil 
used in normal chow) or linseed oil for 2 months and subjected 
to a food allergy model with ovalbumin (OVA) as the allergen. 
Mice maintained with linseed-oil-containing chow exhibited less 
diarrhea incidence caused by OVA-induced food allergy than 
did those raised on chow containing soybean oil (22). Similarly, 
dietary fish oil has the same effect on the intestinal allergy (23, 
24). We further revealed that the fatty acid composition of intes-
tinal tissue from these mice was correlated with the fatty acid 
compositions of their diets: the colons of mice raised on chow 
containing linseed oil contained higher concentrations of ALA 
acid and its metabolites EPA and DHA (Figure 1), whereas those 
of mice raised on chow containing soybean oil contained high 
levels of LA and its metabolite arachidonic acid (22). These results 
indicated that the relative proportions of ω3 and ω6 fatty acids in 
dietary oils determine the composition of ω3 and ω6 fatty acids 
and their metabolites in the intestines.
CONveRSiON OF ePA TO ANTi-ALLeRGiC 
LiPiD MeTABOLiTe FOR THe CONTROL 
OF FOOD ALLeRGY
As has already been mentioned, the physiological activity exhib-
ited by the metabolites of EPA and DHA is now coming under 
the spotlight in the area of nutritional or food immunology (6, 
11). We employed lipidomics technology to carry out a compre-
hensive analysis of fatty acid metabolites, allowing us to identify 
the fatty acid metabolites increased in the colons of mice raised 
on linseed-oil-containing chow. We found a marked increase in 
the content of 17,18-epoxyeicosatetraenoic acid (17,18-EpETE), 
a metabolite produced by the action of CYP on EPA as the sub-
strate (Figure 1) (22). We then used synthetic 17,18-EpETE to 
test the anti-allergic effect of 17,18-EpETE and found that mice 
FiGURe 1 | Metabolic pathway in the generation of anti-allergic/
inflammatory lipid mediators from the dietary oil. ALA is enriched in 
some kinds of dietary oil (e.g., linseed oil) and absorbed into the intestinal 
tissues where it is metabolized into EPA after several reactions mediated by 
various enzymes (e.g., elongase and desaturases). EPA is epoxidized by 
CYP450 to generate 17,18-EpETE, which exerts anti-allergic properties in the 
intestine. Abbreviations: ALA, α-linolenic acid; CYP, cytochrome P450; EPA, 
eicosapentaenoic acid; EpETE, epoxy eicosatetraenoic acid; LA, linoleic acid; 
OA, oleic acid; PA, palmitic acid; SA, stearic acid.
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that received 17,18-EpETE administration exhibited the same 
reduced incidence of allergic diarrhea seen in mice fed linseed-
oil-containing chow (Figure 1) (22).
17,18-EpETE is metabolized to 17,18-dihydroxyeicosatetrae-
noic acid (17,18-diHETE) by the action of epoxide hydrolase, 
which cleaves the epoxy ring (25). The colons of mice raised 
on linseed-oil-containing chow also contained high levels of 
17,18-diHETE in addition to 17,18-EpETE. However, unlike 
17,18-EpETE, 17,18-diHETE had almost no effect in suppressing 
allergic diarrhea (22), suggesting that 17,18-EpETE may be the 
active molecule in the EPA-derived lipid mediator that suppresses 
intestinal allergy. In light of previous debates about the possibil-
ity that epoxide hydrolase inhibition may improve circulatory 
disorders, such as hypertension and arteriosclerosis, as well as 
chronic inflammatory disorders, such as colitis and arthritis 
(26, 27), inhibiting the metabolic conversion of 17,18-EpETE 
to 17,18-diHETE by blocking the action of epoxide hydrolase 
might further suppress the development of intestinal allergy. 
CYP, which is a responsible enzyme to generate 17,18-EpETE 
from EPA, exists in a range of different subfamilies and types 
(28). Collectively, these findings suggest that it will be important 
not only to identify anti-allergic/anti-inflammatory lipids but 
also to consider the various metabolic pathways involved in lipid 
production, metabolism, and decomposition for the develop-
ment of novel prevention and treatment strategies for allergies 
and inflammatory disorders based on the knowledge of lipid 
mediators and its related metabolites.
SPHiNGOSiNe 1-PHOSPHATe AS AN 
iNTeSTiNAL iMMUNOMODULATORY 
FACTOR FOR igA ReSPONSeS
Sphingosine 1-phosphate (S1P) is a type of sphingolipid that 
is a focus of attention as a lipid mediator involved in immu-
nomodulation (29, 30). In the body, S1P is mainly generated via 
the sphingomyelin → ceramide → sphingosine → S1P pathway 
by the action of sphingomyelinase, ceramidase, and sphingosine 
kinase, respectively (Figure  2). Furthermore, S1P is returned 
to sphingosine by the action of phosphatase or is irreversibly 
decomposed by S1P lyase. The balance between production, 
decomposition, and metabolism is carefully regulated to form a 
gradient of S1P concentration in the body, which controls the cell 
trafficking, such as the emigration of thymocytes and lymphocytes 
from the thymus and secondary lymphatic tissues, respectively 
(31). Given that S1P is also involved in the immune reactions of 
a wide range of cells, including T cells, macrophages, dendritic 
cells, and vascular endothelial cells, it is attracting attention as an 
important lipid mediator responsible for key immune functions 
in the immunosurveillance and immune diseases (31).
We have previously shown that S1P plays important roles in 
physiological and pathological circumstances of the intestinal 
immune system (32). For example, S1P receptor expression is 
changed during B cell differentiation in the Peyer’s patches, a 
major organized mucosa-associated lymphoid tissue for the 
initiation of antigen-specific IgA immune responses (33). Upon 
the class switching to IgA+ B cells, naïve B cells decrease the S1P 
receptor expression, which allows their retention in the Peyer’s 
patches. Then, IgA+ B cells show the recovered expression of S1P 
receptors for the emigration from the Peyer’s patches. Similarly, 
peritoneal B cells, which contain B1 B and B2 B cells for the 
antibody production against T-independent and -dependent 
antigens, respectively, express high levels of S1P receptors and 
thus use the S1P for their trafficking into the intestinal compart-
ments (34, 35). For this reason, mice administered FTY720 to 
inhibit the S1P pathway by inducing the internalization of S1P 
receptors exhibit a reduced intestinal IgA antibody reaction to 
oral vaccines (Figure 2) (33, 35).
Another example is trafficking of specialized T cells in the 
epithelial layers of the intestine, which are known as intraepi-
thelial lymphocytes (IELs). They eliminate pathologic epithelial 
cells and maintain the function of “healthy” epithelial functions 
as the front line of defense (36). IELs include subtypes [e.g., 
T cells expressing T cell receptor (TCR) αβ or γδ] and display 
different S1P dependencies in the migration from the thymus to 
the intestinal epithelium. Indeed, FTY720 treatment resulted in 
the selective reduction of IELs expressing TCRαβ in the colon, 
whereas colonic IELs expressing TCRγδ were insensitive to 
FiGURe 2 | Two pathways for the generation of sphingolipids in the control of immune responses in the intestine. Palmitic acid is absorbed from dietary 
oil (e.g., palm oil) into the intestinal tissue where it directly stimulates IgA-producing plasma cells to enhance IgA production. Simultaneously, palmitic acid is 
metabolized into the sphingolipids, such as ceramide, sphingosine, and sphingosine 1-phosphate. In the other pathway, sphingomyelin abundantly present in the 
diets, such as beef, milk, and egg is metabolized into ceramide and then to sphingosine in the intestinal lumen. Both ceramide and sphingosine are absorbed into 
the intestinal tissue where they are further metabolized into the sphingosine 1-phosphate. Sphingosine 1-phosphate regulates cell trafficking and thus controls the 
IgA antibody responses to oral antigen. It also participates in the development of food allergy by controlling T and mast cell trafficking and/or growth.
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FTY720 treatment, which provides immunological diversity at 
the front of body surface (37).
SPHiNGOSiNe 1-PHOSPHATe MeDiATeS 
THe DeveLOPMeNT OF iNTeSTiNAL 
iMMUNe DiSeASeS
S1P has also been shown to contribute to the development of 
immune disorders. In an analysis of murine food allergy model 
that we mentioned above, we discovered that S1P involved in 
the occurrence of allergic diarrhea. Hence, the development of 
allergic diarrhea was prevented by FTY720 administration (38). 
In FTY720-treated mice, no change was noted in the allergen-
specific IgE production, whereas infiltration of IL-4-producing 
pathogenic T cells into the colon was inhibited. Also, the increase 
of mast cells in the colon was also prevented in the mice receiving 
FTY720 treatment. In addition to the trafficking of mast cells, S1P 
is produced by mast cells, which regulate their maturation and 
phenotype, and responsiveness (39–41).
Similarly, FTY720 administration has also been shown to be 
effective in the prevention of intestinal inflammation by blocking 
S1P-dependent pathogenic cell trafficking (e.g., IFN-γ-producing 
T cells) (42). Thus, S1P plays a critical role in the control of traf-
ficking of pathogenic cells, which could be a prospective target for 
the control of intestinal immune diseases (e.g., food allergy and 
intestinal inflammation).
SPHiNGOLiPiD MeTABOLiSM FOR THe 
iNDUCTiON OF iMMUNe ReSPONSeS iN 
THe iNTeSTiNe
In terms of sources of S1P and related sphingolipids in the intes-
tine, the S1P precursor sphingomyelin is found in large quanti-
ties in foods, such as meat, milk, and eggs (Figure 2). Because 
almost all bacteria lack sphingolipids, there is almost no change 
in the sphingolipid content of the gut of germ-free animals when 
compared with conventional/specific pathogen-free mice (43). 
As such, most sphingolipids in the intestinal environment are 
likely to be derived from dietary sources. Dietary sphingomyelin 
is actually metabolized to ceramide and sphingosine by the action 
of a group of enzymes expressed in intestinal epithelial cells and 
absorbed, after which it is converted to S1P by sphingosine kinase 
(Figure 2) (44, 45). Consequently, high levels of sphingolipids are 
detected in the intestines (46).
Sphingolipids are also synthesized in the body de novo via a 
pathway that originates with palmitic acid (Figure 2). We have 
demonstrated that palmitic acid acts to increase antibody pro-
duction. Mice raised on a special chow with an increased palmitic 
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acid content or chow manufactured from palm oil, which has a 
high palmitic acid content, excreted more IgA antibodies in their 
feces (Figure  2) (47). These mice also exhibited an enhanced 
intestinal antigen-specific IgA antibody response to oral vaccines. 
We identified a pathway for this effect, in which palmitic acid 
acts directly on IgA antibody-producing cells and increases the 
generation of IgA antibodies (Figure 2) (47). Furthermore, we 
also identified a pathway in which the sphingolipids, generated 
when palmitic acid is metabolized by serine palmitoyltransferase, 
increase IgA antibody-producing cells in the colon (47). Taken 
together, the production, metabolism, and recognition of sphin-
golipids, mediated by intracorporeal and extracorporeal factors, 
are implicated in a wide range of intestinal immune reactions.
CONCLUSiON
Although the number of patients with food allergies, inflam-
matory bowel disease, and other mucosal immune disorders is 
increasing recently, little therapy and prevention are available now. 
Recent developments in lipidomics technology have made it pos-
sible to carry out comprehensive analyses of the lipid metabolism 
network in the body. Owing to these newly developed techniques, 
novel preventive and therapeutic target candidates for immune 
disorders have been identified. In addition, these technologies 
can be used for the development of lipid-based safe and effective 
adjuvant to enhance the vaccine effects. Thus, the formation 
of the lipid network, including dietary lipids, will become an 
increasingly important topic of research in the basic biology area 
as well as the drug and vaccine development for the control of 
immune disorders and infectious diseases.
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